Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-21
    E.g., 2018-10-21

Archive Search

Pages

645 items
1:23 PM, Oct 05, 2018  |  BC Week In Review | Financial News  |  Amended Offerings

Allogene IPO could be year's largest biotech listing on NASDAQ

In newly proposed terms for its planned IPO on NASDAQ, cell therapy start-up Allogene Therapeutics Inc. (South San Francisco, Calif.) hopes to sell 16 million shares at $16-$18. At the midpoint, Allogene would raise $272...
1:20 PM, Oct 05, 2018  |  BC Week In Review | Financial News  |  Amended Offerings

Osmotica amends IPO

Drug delivery and generics company Osmotica Pharmaceuticals plc (Bridgewater, N.J.) amended on Oct. 1 its proposed IPO on NASDAQ and now plans to sell 8.3 million shares between $14-$16. The company also added Wells Fargo...
10:22 AM, Sep 28, 2018  |  BC Week In Review | Financial News  |  Amended Offerings

Kodiak amends IPO

Ophthalmic company Kodiak Sciences Inc. (Palo Alto, Calif.) amended on Sept. 24 its proposed IPO on NASDAQ and now plans to sell 9 million shares at $13-$15. At the midpoint of its proposed range, the...
10:37 AM, Sep 21, 2018  |  BC Week In Review | Financial News  |  Amended Offerings

Sutro amends IPO

Autoimmune and cancer company Sutro Biopharma Inc. (South San Francisco, Calif.) amended on Sept. 17 its IPO on NASDAQ and now plans to sell 5 million shares at $14-$16. At the midpoint, the company would...
9:33 AM, Sep 21, 2018  |  BC Week In Review | Financial News  |  Amended Offerings

Arvinas amends IPO

Protein degradation company Arvinas LLC (New Haven, Conn.) amended on Sept. 14 its proposed IPO on NASDAQ and now plans to sell 6.7 million shares at $14-$16. The offering is being underwritten by Goldman Sachs,...
9:32 AM, Sep 21, 2018  |  BC Week In Review | Financial News  |  Amended Offerings

Gritstone amends IPO

Immuno-oncology company Gritstone Oncology Inc. (Emeryville, Calif.) amended on Sept. 17 its proposed IPO on NASDAQ and now plans to sell 6.1 million shares at $13-$15. At the midpoint, the company would raise $85 million...
3:44 PM, Sep 13, 2018  |  BC Week In Review | Financial News  |  Amended Offerings

Y-mAbs amends IPO

Cancer company Y-mAbs Therapeutics Inc. (New York, N.Y.) amended its proposed NASDAQ IPO on Sept. 7 and now plans to sell 5.3 million shares at $14-$16. The offering is being underwritten by BofA Merrill Lynch,...
9:27 AM, Aug 10, 2018  |  BC Week In Review | Financial News  |  Amended Offerings

Aridis amends IPO

Immunotherapy company Aridis Pharmaceuticals Inc. (San Jose, Calif.) amended its NASDAQ IPO on Aug. 6 and now plans to sell 2 million shares at $13-$15. The offering is being underwritten by Cantor Fitzgerald, Maxim, Laidlaw,...
12:13 PM, May 18, 2018  |  BC Week In Review | Financial News  |  Amended Offerings

Iterum sets IPO range

Antibiotics company Iterum Therapeutics plc (Dublin, Ireland) amended its proposed IPO on NASDAQ on May 16 and now plans to sell 5.3 million shares at $14-$16. At the $15 midpoint, the company would raise $80...
10:20 AM, Apr 13, 2018  |  BC Week In Review | Financial News  |  Amended Offerings

Morphosys amends NASDAQ listing

MorphoSys AG (Xetra:MOR; Pink:MPSYY) amended its proposed NASDAQ listing on April 9 and now plans to raise about $200 million through the sale of 8.3 million ADSs at $24.12 in a follow-on underwritten by Goldman...

Pages